...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gynecologic Oncology: An International Journal >A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172.
【24h】

A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172.

机译：妇科肿瘤学小组研究与腹腔化疗相比，经腹膜内治疗的III期最佳减灭性卵巢癌患者血清CA-125水平：对GOG 172入组患者的分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Serum CA-125 values have been advocated in the monitoring of ovarian cancer patients receiving intravenous (IV) chemotherapy. This evaluation sought to determine if the CA-125 test can be used to monitor treatment effect among patients receiving intraperitoneal chemotherapy (IP). METHODS: Patient charts from a phase III clinical trial (GOG 172) were retrospectively reviewed. Serum CA-125 levels prior to each cycle of therapy were collected and compared between the IV and IP chemotherapy delivery. The association between CA-125 and progression-free survival (PFS) or overall survival (OS) was estimated and the homogeneity of the results between IP and IV chemotherapy was assessed. RESULTS: A total of 177 patients were treated with IV chemotherapy and 165 patients with IP chemotherapy with CA-125 data available were included in this analysis. The observed difference was not statistically significant in median CA-125 levels between the IV and IP arms at any time point (P>0.05 for all). Following surgery and adjuvant chemotherapy, patients with an abnormal CA-125 >35 U/ml were 2.45 times more likely to have disease progression (95% CI: 1.52-3.95, P<0.001) and 2.78 times more likely to die of disease (95% CI: 1.66-4.65, P<0.001), compared to those with a CA-125 <35 U/ml. These results were consistent with IP and IV chemotherapy. CONCLUSION: Serum CA-125 levels decrease in a similar manner during IP chemotherapy when compared to IV chemotherapy. Serum CA-125 algorithms for monitoring treatment effect that have been established for IV chemotherapy may also be applied for patients receiving IP chemotherapy.
机译：目的：在监测接受静脉内（IV）化疗的卵巢癌患者中主张血清CA-125值。该评估旨在确定CA-125测试是否可用于监测接受腹膜内化疗（IP）的患者的治疗效果。方法：回顾性地回顾了III期临床试验（GOG 172）的患者病历。收集每个治疗周期之前的血清CA-125水平，并在IV和IP化疗之间进行比较。评估了CA-125与无进展生存期（PFS）或总生存期（OS）之间的关联，并评估了IP和IV化疗结果的均一性。结果：共有177例患者接受了IV化疗，165例IP化疗了CA-125数据。在任何时间点，IV组和IP组之间观察到的中值CA-125水平差异均无统计学意义（所有P> 0.05）。手术和辅助化疗后，CA-125> 35 U / ml异常的患者患病进展的可能性高2.45倍（95％CI：1.52-3.95，P <0.001），而死于疾病的可能性高2.78倍（与CA-125 <35 U / ml的CI相比，95％CI：1.66-4.65，P <0.001）。这些结果与IP和IV化疗一致。结论：与静脉化疗相比，IP化疗期间血清CA-125水平下降的方式相似。针对IV化疗建立的用于监测治疗效果的血清CA-125算法也可用于接受IP化疗的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号